Evidence map›Paper›PMID 41473491›Full record

ArticlePrzeglad gastroenterologiczny2025

One-year single-center follow-up study of ustekinumab and vedolizumab use in inflammatory bowel disease Egyptian patients as second-line therapy after anti-TNF failure.

Shimaa Kamel, Waleed Hamed Abd Alaty, Heba Rashad, Dina Fathy, Mohamed Abdel-Samiee, Ibrahim Hindy, Ahmed Shaban, Safaa Askar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Przeglad gastroenterologiczny, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shimaa KamelTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Waleed Hamed Abd AlatyTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Heba RashadTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Dina FathyTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mohamed Abdel-SamieeDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
Ibrahim HindyTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Ahmed ShabanDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom, Egypt.
Safaa AskarTropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Inflammatory bowel disease (IBD) is mainly treated medically, especially with the availability of biological agents. Although anti-TNF drugs have been the only biological drugs available to treat ulcerative colitis (UC) and Crohn's disease (CD) patients for too many years, recently novel biological therapies have been approved for therapy. Using these novel agents as second-line biological therapies has proven to have a good effect on the induction and maintenance of remission of these diseases. Aim: To evaluate the effectiveness of second-line biologics (ustekinumab and vedolizumab) after an anti-TNF agent failure. Material and methods: From 50 IBD patients receiving biological therapy, 26 patients with severe UC and CD receiving vedolizumab and ustekinumab for 1 year were chosen for this observational and cross-sectional study. Results: 80% of CD patients received vedolizumab, while 75% of UC patients received ustekinumab. UC activity as indicated by the Mayo Scoring Index significantly decreased during follow-up, while CD activity as indicated by Crohn's Disease Activity Index (CDAI) did not significantly decrease with the rise of inflammatory markers, which could be due to the small number of IBD patients who received vedolizumab and ustekinumab. Conclusions: There was superior effectiveness of ustekinumab compared to vedolizumab in treating UC patients with prior anti-TNF treatment failure.

Indexed as

Crohn’s Disease Activity Indexinflammatory bowel diseaseMayo Scoring Indexustekinumabvedolizumab

Identifiers

PMID41473491
PMCPMC12746575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.